This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Lilly (LLY) Phase III Eczema Study on Lebrikizumab Meets Goal
by Zacks Equity Research
Eli Lilly's (LLY) two phase III studies on lebrikizumab meet the primary and all key secondary endpoints.
Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev
by Zacks Equity Research
Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.
Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA
by Zacks Equity Research
Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.
Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
Nektar (NKTR) Q2 Earnings and Revenues Top, Pipeline On Track
by Zacks Equity Research
Nektar (NKTR) reports encouraging second-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
Radius (RDUS) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Radius (RDUS) reports a narrower loss but misses on sales in the second quarter. The company also lowers guidance for lead drug Tymlos.
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, SNY's TBIO Buyout, FDA Updates
by Kinjel Shah
Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce Q2 results. FDA approves AstraZeneca's (AZN) lupus medicine, Saphnelo. Sanofi (SNY) to buy Translate Bio.
Novo Nordisk's (NVO) Q2 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) delivers better-than-expected results for Q2. Sales are aided by growth in Diabetes and Obesity Care owing to elevated GLP-1 revenues.
United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up
by Zacks Equity Research
United Therapeutics (UTHR) second-quarter earnings and sales beat estimates. Higher sales of Orenitram, Unituxin and Tyvaso mainly drive the top line in the quarter.
Amgen (AMGN) Q2 Earnings Top, COVID-Led Sales Woes to Linger
by Zacks Equity Research
Amgen (AMGN) beats Q2 estimates for both earnings and sales. It expects the pandemic to continue to hurt sales growth in the second half of 2021.
Incyte (INCY) Q2 Earnings & Sales Beat on Solid Jakafi Growth
by Zacks Equity Research
Incyte (INCY) beats earnings and sales estimates in the second quarter as Jakafi sales register growth.
Eli Lilly (LLY) Q2 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) reports mixed second-quarter results and ttightens 2021 sales forecast. Stock down in pre-market trading.
Eli Lilly (LLY) Lags Q2 Earnings Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of -1.06% and 2.62%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
A Hint Towards a Taper - But No Tantrum
by David Borun
Stocks were little changed during a week that could have been quite eventful.
Drug/Biotech Stock Q2 Earnings on Aug 3: LLY, AMGN & More
by Kinjel Shah
Let us take a look at four drug/biotech companies, LLY, AMGN, INCY and ALNY, which are gearing up for their earnings release.
What's in Store for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla Repatha and other and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.
Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV
by Kinjel Shah
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $243.58, moving +0.15% from the previous trading session.
Eli Lilly (LLY) Reports Next Week: What You Should Expect
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.
Pfizer (PFE) Inks Vaccine Deal, Faces FDA Delay on JAK Drugs
by Zacks Equity Research
Pfizer (PFE) partners with Biovac for manufacturing and distributing its COVID-19 vaccine in African Union. The FDA delays decision on Pfizer's regulatory filings for JAK inhibitors.
The Zacks Analyst Blog Highlights: Exxon Mobil, Eli Lilly, Costco, Aon and EOG Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, Eli Lilly, Costco, Aon and EOG Resources
Top Stock Reports for Exxon Mobil, Eli Lilly & Costco
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Eli Lilly (LLY), and Costco Wholesale (COST).